Evidence map›Paper›PMID 32006297›Full record

ArticleMolecular diversity2021

A novel pregnene analogs: synthesis, cytotoxicity on prostate cancer of PC-3 and LNCPa-AI cells and in silico molecular docking study.

Nabeel A Abdul-Rida, Ali M Farhan, Najim A Al-Masoudi, Bahjat A Saeed, Dannah Miller, Ming-Fong Lin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Targeting treatment options for castration-resistant prostate cancer.American journal of clinical and experimental urology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nabeel A Abdul-RidaDepartment of Chemistry, College of Science, University of Al-Qadisiya, Al-Qadisiya, Iraq.
Ali M FarhanDepartment of Chemistry, College of Science, University of Al-Qadisiya, Al-Qadisiya, Iraq.
Najim A Al-MasoudiDepartment of Chemistry, College of Science, University of Basrah, Basrah, Iraq. najim.al-masoudi@gmx.de.ORCID http://orcid.org/0000-0001-6811-191X
Bahjat A SaeedDepartment of Chemistry, College of Education for Pure Science, University of Basrah, Basrah, Iraq.
Dannah MillerDepartment of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Ming-Fong LinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, NE, 68198-5870, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New pregnene analogs of N-hydroxamic acid 6, imino-propane hydrazides 7 and 8 as well as the aryl amides 9-11, oxadiazole, pyrazole and sulfinyl analogs 13-15, via the hydrazide analog 5 of methyl ((5-pregnen-3β,17β-diol-15α-yl)thio)propanoate (4) were synthesized. The in vitro cytotoxic activities of selected synthesized steroids against two human prostate cancer cell lines (PC-3, and LNCaP-AI) were evaluated by MTT assay. Compound 10 was the most active cytotoxic agent among these steroids against PC-3 and LNCaP-AI cell lines with inhibition of 96.2%, and 93.6% at concentration levels of 10.0 μM and 91.8%, and of 79.8% at concentration of 1.0 μM, respectively. Molecular docking study of 10 showed a hydrogen bonding with the amino acid Asn705 residue of the receptor 1E3G, together with hydrophobic interactions. Therefore, compound 10 can be considered as a promising anticancer agent due to its potent cytotoxic activity.

Indexed as

Antineoplastic AgentsPregnenesCell Line, TumorCell SurvivalHumansMaleMolecular Docking SimulationProstatic NeoplasmsReceptors, AndrogenAntineoplastic AgentsAR protein, humanPregnenesReceptors, AndrogenAmidesAnticancer activityMolecular docking studyOxadiazolePregnene analogsPyrazole

Identifiers

PMID32006297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.